Asserta Global Healthcare Solutions

What Asserta Global Healthcare Solutions does

Asserta Global Healthcare Solutions is a Barcelona-based private healthcare technology company specializing in Integrated Pharmacotherapy Governance for hospitals and outpatient providers. Founded as a Sociedad Limitada and operating across 20+ countries in Europe, Latin America, and the Middle East, the company serves 194 healthcare institutions, including 76 hospitals and more than 600 primary care centers, addressing public hospitals, private healthcare networks, primary care organizations, and health authorities. Its proposition is the structuring of the complete medication lifecycle — from procurement and electronic prescribing through administration and outcomes — via integrated software rather than point solutions.

The company's product portfolio is anchored by two proprietary platforms. Silicon NextGen is an operational core that integrates with Hospital Information Systems (HIS), Electronic Health Records (EHR), pharmacy management systems, and automated dispensing technologies to govern the end-to-end pharmacotherapy cycle. Silicon Advanced Analytics is an institutional intelligence suite comprising Pharmacy Analytics Manager, Fleming antimicrobial stewardship (PROA), and OncoAnalytics, layered on top of a dataset that has processed over 2 billion records, 125 million patient episodes, and 400 million administered doses. The portfolio is augmented by a Real-World Research service that supports Phase IV studies and health economics assessments using the installed hospital network, and a Strategy consulting practice built around the proprietary Asserta 360° Assessment Framework.

Asserta operates an enterprise sales-led go-to-market, engaging directly with hospital executives, pharmacy directors, and IT decision-makers through multi-year subscription contracts and professional services engagements. Revenue is generated through software licensing (approximately 60% IT-related per company disclosure) and strategic consulting plus clinical management services (approximately 40% combined), with international research consultancy work for global pharmaceutical companies accounting for roughly 30% of total revenue. Distribution is supported by direct enterprise sales, partnerships with healthcare technology vendors, and active participation in three EU Horizon Programme consortia (CLOSER, Share4Rare, MyHealth). Geographic operations span Spain, the United Kingdom, Italy, Austria, the Czech Republic, and Saudi Arabia in Europe and the Middle East, and Argentina, Chile, Uruguay, Peru, and Mexico in Latin America.

Name

Asserta Global Healthcare Solutions

Legal name

ASSERTA GLOBAL HEALTHCARE SOLUTIONS, S.L.

Website

https://asserta.net

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Asserta Global Healthcare Solutions is a Barcelona-based private healthcare technology company providing Integrated Pharmacotherapy Governance software, advanced analytics, and consulting to 194 healthcare institutions across 20+ countries, primarily hospitals and primary care networks in Europe, Latin America, and the Middle East.

Ownership category

akta.pro rank

Product category

Hospital Pharmacy Software

NAICS

Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292), Management Consulting Services (54161)

SIC

Services-Health Services (8000)

akta.pro primary industry

Pharmacy Benefit Management (PBM) & Formulary Management IT (HLACAKAD)

Keywords

• Pharmacotherapy governance software
• Hospital pharmacy analytics
• Antimicrobial stewardship platform
• Clinical decision support
• Healthcare data analytics

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Software Platform Licensing (Silicon NextGen): Licensing of Silicon NextGen operational platform for pharmacotherapy governance. Implementation includes integration with hospital systems, training, and ongoing support.
2. Analytics Platform Subscription (Silicon Advanced Analytics): Subscription-based access to institutional intelligence suites including Pharmacy Analytics Manager, Fleming PROA, and OncoAnalytics with real-time dashboards and KPI monitoring.
3. Strategic Consulting Services: Strategic transformation design services including institutional readiness assessment, governance alignment, digital transformation roadmaps, and change management programs. Revenue mix approximately 30% international research consultancy and 20% clinical management.
4. Real-World Research Services: Research consulting including Phase IV post-marketing studies, observational studies, health outcome evaluations, economic assessments, registry development, and clinical trial support. Approximately 30% of revenue from international research consultancy.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Asserta Global Healthcare Solutions delivers an Integrated Pharmacotherapy Governance Ecosystem for hospitals and healthcare institutions, centered on the Silicon NextGen operational platform that structures the complete medication lifecycle (acquisition through administration) and the Silicon Advanced Analytics suite that provides real-time institutional intelligence, antimicrobial stewardship, and oncology analytics. The portfolio is complemented by Real-World Research services generating evidence for clinical, regulatory and market access decisions, and Strategy consulting built on the Asserta 360° Assessment Framework.

Product overview

Asserta Global Healthcare Solutions offers an Integrated Pharmacotherapy Governance Ecosystem composed of four interconnected solution pillars: (1) Silicon NextGen as the operational core platform that structures, integrates, and governs the complete medication lifecycle from acquisition through point-of-care administration in hospital and outpatient settings; (2) Silicon Advanced Analytics as the institutional intelligence layer providing real-time analytics, executive dashboards, and performance monitoring, comprising three specialized modules — Pharmacy Analytics Manager for comprehensive pharmacy operations intelligence, Fleming Antimicrobial Stewardship for resistance monitoring and protocol governance, and OncoAnalytics for oncology treatment transparency; (3) Real-World Research providing evidence generation for clinical, regulatory, and market access decisions embedded within actual clinical practice; and (4) Strategy providing strategic transformation design through the Asserta 360° Assessment Framework. The portfolio is architected as a self-reinforcing virtuous cycle where operations generate structured data, intelligence refines governance, and evidence informs redesign.

Differentiator

Problem solved

Functional benefit

Products and services

• Silicon NextGen An integral operational platform that structures, integrates, and governs the complete pharmacotherapy cycle in hospital and outpatient settings, providing a unified operational backbone from acquisition and supply chain through sterile preparation, dispensing, electronic prescribing, barcode-assisted administration, and electronic medication administration records (eMAR). Built for hospitals, health systems, and integrated care networks.
• Silicon Advanced Analytics An institutional intelligence suite providing real-time analytics to strengthen pharmacotherapy governance, support executive decision-making, and enable cost-performance alignment. Includes Pharmacy Analytics Manager, Fleming PROA antimicrobial stewardship module, and OncoAnalytics oncology governance module, with Explainable AI methodologies for algorithmic transparency and audit-readiness.
• Real-World Research Applied real-world evidence generation service for clinical, regulatory, and market access decisions, embedded within real clinical operations and aligned with institutional governance and regulatory requirements. Includes Phase IV post-marketing studies, observational studies, health outcome evaluations, economic assessments, registry development, and clinical trial support.
• Strategy (Strategic Consulting) Strategic design service for complex clinical digital transformation, providing institutional readiness assessment (via the Asserta 360° Assessment Framework), governance alignment, digital transformation roadmaps, and change management programs for healthcare organizations.

Quantifiable outcome

• 2,000,000,000+ records processed
• +4 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

14 partnerships are on record, tiered core and major.

• Hospital Sant Joan de Déu BarcelonacoreStrategic or Co-development PartnerResearch partner in CLOSER project for childhood leukemia survival equity between Latin America and Europe. Joint epidemiological study on leukemia subtypes in Latin American countries.
• Vall d'Hebron Institut de Recerca (VIR)coreStrategic or Co-development PartnerEU research consortium partner. Collaborates on pharmacotherapy governance research and real-world evidence generation.
• Josep Carreras Leukaemia Research InstitutecoreStrategic or Co-development PartnerResearch partner in CLOSER project addressing childhood leukemia research across Europe and Latin America.
• Istituto Superiore di Sanità (Italy)majorStrategic or Co-development PartnerEU research consortium partner in CLOSER project. National health research institute providing scientific expertise.
• Newcastle University (UK)majorStrategic or Co-development PartnerAcademic partner in CLOSER project contributing epidemiological research expertise to childhood leukemia study.
• St. Anna Kinderkrebsforschung (Austria)majorStrategic or Co-development PartnerChildren's cancer research partner in CLOSER project focusing on improving leukemia outcomes.
• Charité BerlinmajorStrategic or Co-development PartnerEuropean university hospital partner in research consortium for pharmacotherapy governance and real-world evidence.
• Hospital de Pediatría SAMIC Prof. Dr. Juan P. Garrahan (Argentina)coreStrategic or Co-development PartnerCLOSER project partner in Argentina - leading pediatric hospital for childhood leukemia research in Latin America.
• Fundación Pérez Scremini (Uruguay)coreStrategic or Co-development PartnerCLOSER project partner - pediatric oncology foundation in Uruguay working on childhood leukemia survival improvement.
• Keralty (Latam)majorStrategic or Co-development PartnerHealthcare network partner in Latin America for pharmacotherapy governance implementation and healthcare digitalization projects.
• European Commission (EU Horizon Programme)coreStrategic or Co-development PartnerFunding and consortium coordination partner for 3 EU Horizon Programme projects: CLOSER, Share4Rare, and MyHealth. Active in EU Health Programme initiatives.
• Pharmaceutical CompaniesmajorStrategic or Co-development PartnerIndustry partners for Real-World Research services including Phase IV post-marketing studies, risk-sharing agreement monitoring, rare disease registries, advanced therapy monitoring, and health economics evaluations.
• Global Health OrganizationsmajorStrategic or Co-development PartnerInternational health organizations collaborating on pharmacotherapy governance programs and healthcare modernization initiatives.
• Health AuthoritiescoreStrategic or Co-development PartnerGovernment health ministries and regulatory bodies for national pharmacotherapy modernization, antimicrobial resistance programs, and healthcare digitalization.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• VigiLanz: Clinical surveillance and antimicrobial stewardship platform serving hospitals — closely overlapping with Asserta's Fleming PROA antimicrobial stewardship module and broader institutional analytics focus.
• Mediware (WellSky): Specialty pharmacy and medication management software provider for hospital and outpatient settings — comparable niche overlap with Asserta's specialty pharmacy and oncology analytics positioning.

Direct peers

• First Databank (FDB): Drug knowledge and medication decision support vendor whose drug database and clinical decision support tools underpin pharmacy analytics workflows comparable to Asserta's Silicon Advanced Analytics suite.
• Omnicell: US-listed provider of hospital pharmacy automation and medication management solutions, including central pharmacy, sterile compounding, and analytics — directly comparable to Asserta's Silicon NextGen platform in the hospital pharmacy operations space.
• Wolters Kluwer (Clinical Solutions): Provider of clinical decision support and drug information platforms (Medi-Span, UpToDate, Sentri7) — directly comparable to Asserta's pharmacy analytics, antimicrobial stewardship, and clinical decision support modules.

Broad incumbents

• McKesson: Pharmaceutical distribution and pharmacy services giant with analytics and clinical decision tools serving hospital pharmacies — comparable at the level of pharmacotherapy intelligence and supply chain governance.
• Becton Dickinson (BD): Global medical technology company offering medication management solutions including dispensing, barcode verification, and pharmacy analytics — overlapping with Asserta's end-to-end medication lifecycle platform.
• Epic Systems: Largest US hospital EHR vendor with its own pharmacy, ePrescribing, and analytics capabilities — sets the integration baseline Asserta must connect to and compete against for specialty pharmacy analytics.
• Allscripts (Veradigm): HIS/EHR vendor with embedded ePrescribing, medication administration, and analytics — competes in the same hospital pharmacy IT procurement cycles as Asserta.
• Oracle Health (formerly Cerner): Dominant hospital EHR/HIS vendor embedding pharmacy, ePrescribing, and analytics into its inpatient suite — competes with Asserta at the integrated-pharmacotherapy level across large hospital systems.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/asserta

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asserta Global Healthcare Solutions